SCHEMBL4315155

SCHEMBL4315155

COCCOc1ccc(/C=C/c2n[nH]c3ccccc23)c([N+](=O)[O-])c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 2/20 0.41
AURKA O14965 1/20 0.38
AURKB Q96GD4 1/20 0.38
KMT2A Q03164 5/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
GRM4 Q14833 1/20 0.38
PIM1 P11309 1/20 0.37
CYP19A1 P11511 1/20 0.37
MAPT P10636 5/20 0.37
NTRK1 P04629 1/20 0.36
NTRK3 Q16288 1/20 0.36
NTRK2 Q16620 1/20 0.36
MEN1 O00255 4/20 0.36
MAPK1 P28482 3/20 0.36
CHEK1 O14757 1/20 0.36
FGFR1 P11362 1/20 0.36
KDM4E B2RXH2 1/20 0.36
RECQL P46063 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4315162 1.00 KDR (0.41) KDRAURKAAURKBKMT2ASMN1; SMN2
SCHEMBL4313787 0.83 KDR (0.44) KDRSMN1; SMN2NPC1RAB9AGRM4
SCHEMBL4313776 0.83 KDR (0.44) KDRSMN1; SMN2NPC1RAB9AGRM4
SCHEMBL4314480 0.79 ALK (0.39) KDRAURKAAURKBKMT2ASMN1; SMN2
SCHEMBL4314474 0.79 ALK (0.39) KDRAURKAAURKBKMT2ASMN1; SMN2
SCHEMBL4310317 0.78 MAPT (0.48) KDRAURKAAURKBKMT2ASMN1; SMN2
SCHEMBL4310311 0.78 MAPT (0.48) KDRAURKAAURKBKMT2ASMN1; SMN2
SCHEMBL4314384 0.78 KDM4E (0.47) KDRAURKAAURKBKMT2ASMN1; SMN2
SCHEMBL4314385 0.78 KDM4E (0.47) KDRAURKAAURKBKMT2ASMN1; SMN2
SCHEMBL4322602 0.78 MAPT (0.47) KDRAURKAAURKBKMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101111483-B IGF-1R inhibitors KYOWA HAKKO KIRIN CO.,LTD. (JP) 2011-12-14 CN disclosed
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 US disclosed
CN-101111483-A IGF-1R inhibitors KYOWA HAKKO KOGYO KK (JP) 2008-01-23 CN disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 KDR 75/4885AURKA 3687/4885AURKB 3438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.